There are biotechs. Then there’s MapLight Therapeutics, a Redwood City-born anomaly that didn’t just show up to play, they showed up to rewire the circuitry. And now, with $372.5 million in fresh Series D fuel, they’re not slowing down, they’re targeting the synapses that legacy pharma keeps ghosting.
You want conviction? Look at the names behind this. Christopher A. Kroeger, M.D., MBA, CEO, biotech closer, ex-Biogen, ex-Cardioxyl, a guy who knows how to take a molecule and make it matter. And the science bench? That’s not a bench, that’s a power trio. Karl Deisseroth, M.D., Ph.D., Stanford icon and the literal inventor of optogenetics. Robert C. Malenka, M.D., Ph.D., another Stanford heavyweight whose name is probably etched in the hippocampus of every neuroscience grad student. Then there’s Anatol C. Kreitzer, Ph.D., the basal ganglia whisperer, co-founder and Chief Discovery Officer, whose brain likely functions on a frequency only mice and PhDs can detect.
This round? Led by Forbion and the Life Sciences team at Goldman Sachs Alternatives, with new fire from Sanofi, T. Rowe Price, and Avego BioScience Capital. And yes, the originals are still in, Novo Holdings, 5AM Ventures, Blue Owl Healthcare Opportunities. When the same deep pockets keep doubling down, it says one thing: the science is real, the execution is even better.
MapLight isn’t tossing darts in the dark. They’re building targeted CNS therapeutics off a playbook of optogenetics, spatial transcriptomics, and AI-fed single cell analytics. Think precision meets circuitry, no dopamine splash damage, no spray-and-pray pharmacology. ML-007C-MA is already recruiting in Phase 2 for schizophrenia and Alzheimer’s disease psychosis. ML-004 is pushing through ASD trials. ML-016 is about to step up for Parkinson’s and depression. And ML-009? Watch that one, preclinical but packing heat for hyperactivity and impulsivity.
You don’t raise nearly $700 million just because your slide deck looks cute. You raise it because you’re proving, trial by trial, that targeting the brain’s actual wiring isn’t science fiction, it’s just better science. Their pipeline is clinical-grade, their labs are humming, and their Burlington team is scaling fast. This is what happens when deep tech meets deep purpose and the data backs up the ambition.
Startups Startup Funding Venture Capital Series D Biotech Pharma Healthcare HealthTech Deep Tech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem
If software engineering peace of mind is what you crave, Vention is your zen.
